Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 5:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Muscle-Invasive Bladder Cancer Clear all
Active, not recruiting Phase 3 Interventional

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

NCT03244384
View directory record Official record
Conditions
Localized Renal Pelvis and Ureter Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage II Renal Pelvis and Ureter Cancer AJCC v7, Stage II Ureter Cancer AJCC v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Renal Pelvis and Ureter Cancer AJCC v7, Stage III Ureter Cancer AJCC v7
Interventions
Biospecimen Collection, Clinical Observation, Computed Tomography, CT Urography, Cystoscopy, Magnetic Resonance Imaging, Pembrolizumab, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
914
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 572 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jun 26, 2026, 5:03 AM EDT
Terminated Phase 2 Interventional Results available

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

NCT04871529
View directory record Official record
Conditions
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Interventions
Therapeutic Conventional Surgery, Avelumab, Gemcitabine Hydrochloride, Carboplatin
Procedure · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
92
States / cities
Aurora, Colorado • Highlands Ranch, Colorado • Orlando, Florida + 70 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2024 · Synced Jun 26, 2026, 5:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Addressing Barriers to Palliative Care Use in Bladder Cancer

NCT04598724
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Bladder Cancer Stage II, Bladder Cancer Stage III, Bladder Cancer Stage IV
Interventions
Surveys
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 2, 2023 · Synced Jun 26, 2026, 5:03 AM EDT
Not listed No phase listed Observational

A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

NCT05508568
View directory record Official record
Conditions
Bladder Cancer
Interventions
ADXBLADDER
Diagnostic Test
Lead sponsor
Arquer Diagnostics Ltd
Industry
Eligibility
22 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
13
States / cities
Denver, Colorado • Daytona Beach, Florida • Jeffersonville, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Jun 26, 2026, 5:03 AM EDT
Recruiting Phase 2 Interventional

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

NCT06809140
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma
Interventions
Enfortumab vedotin, Pembrolizumab
Drug
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Duarte, California • Indianapolis, Indiana • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jun 26, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

NCT02690558
View directory record Official record
Conditions
Bladder Cancer
Interventions
pembrolizumab, gemcitabine and cisplatin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jun 26, 2026, 5:03 AM EDT
Completed Phase 1 Interventional

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

NCT05085977
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
TARA-002
Biological
Lead sponsor
Protara Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
Los Angeles, California • Jacksonville, Florida • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Jun 26, 2026, 5:03 AM EDT
Recruiting Phase 2 Interventional

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

NCT07061964
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Pembrolizumab, Photon Beam Radiation Therapy, Positron Emission Tomography, Questionnaire Administration, Transurethral Resection of Bladder Tumor
Procedure · Biological · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
143
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 114 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jun 26, 2026, 5:03 AM EDT
Completed No phase listed Observational

Surveillance for Low and Low-Intermediate Risk Non-muscle Invasive Bladder Cancer: A Pilot Study

NCT02298998
View directory record Official record
Conditions
Bladder Cancer
Interventions
Intervention, Control
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Jun 26, 2026, 5:03 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

NCT04917809
View directory record Official record
Conditions
Bladder Cancer, Recurrent Bladder Cancer, FGFR3 Gene Mutation
Interventions
Erdafitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jun 26, 2026, 5:03 AM EDT
Active, not recruiting Phase 2 Interventional

Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer

NCT04289779
View directory record Official record
Conditions
Bladder Cancer
Interventions
Cabozantinib, Atezolizumab, Cystectomy
Drug · Procedure
Lead sponsor
Deepak Kilari
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
St Louis, Missouri • Hackensack, New Jersey • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Jun 26, 2026, 5:03 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure

NCT02365818
View directory record Official record
Conditions
Bladder Cancer
Interventions
CG0070
Biological
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
17
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Jun 26, 2026, 5:03 AM EDT
Recruiting No phase listed Observational

Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG

NCT05672615
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Cancer
Interventions
Questionnaires, Daily Mood Diaries, Urine Specimen Collection, Research Blood Draw, Utilize excess tissue from a standard of care procedure
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Jun 26, 2026, 5:03 AM EDT
Not listed No phase listed Observational

Measuring Taste Perception During Chemotherapy for Muscle Invasive Bladder Cancer

NCT04567719
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Jun 26, 2026, 5:03 AM EDT
Recruiting Phase 2 Interventional

Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance

NCT05796375
View directory record Official record
Conditions
Non-muscle-invasive Bladder Cancer
Interventions
Cystoscopy, Bladder EpiCheck urine test, Xpert Bladder Cancer Monitor urine test
Procedure · Diagnostic Test
Lead sponsor
White River Junction Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
West Haven, Connecticut • Bay Pines, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 26, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

NCT04919512
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
TAR-200, Cetrelimab
Drug · Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 26, 2026, 5:03 AM EDT
Completed Phase 1 Interventional

Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

NCT04610671
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Bladder Cancer
Interventions
CG0070, Nivolumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 26, 2026, 5:03 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

NCT01200992
View directory record Official record
Conditions
Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium
Interventions
EN3348, Mitomycin C
Biological
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
56
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Jun 26, 2026, 5:03 AM EDT
Recruiting No phase listed Observational

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

NCT07309445
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Neoplasms
Interventions
Not listed
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 26, 2026, 5:03 AM EDT
Terminated Phase 2 Interventional Results available

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

NCT03397394
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Renal Pelvis Carcinoma, Ureter Carcinoma, Urinary Bladder Carcinoma, Urethra Carcinoma, Muscle Invasive Bladder Cancer
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
41
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Jun 26, 2026, 5:03 AM EDT
Not listed No phase listed Observational

Onco4D(TM) Biodynamic Chemotherapy Selection for Bladder Cancer Patients

NCT03739177
View directory record Official record
Conditions
Bladder Cancer
Interventions
Onco4D Biodynamic Chemotherapy Selection Assay
Diagnostic Test
Lead sponsor
Animated Dynamics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Jun 26, 2026, 5:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

NCT06800963
View directory record Official record
Conditions
NMIBC
Interventions
Intravesical Recombinant Mycobacterium (rMBCG)
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Chandler, Arizona • Sacramento, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 26, 2026, 5:03 AM EDT
Active, not recruiting Phase 2 Interventional

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

NCT03609216
View directory record Official record
Conditions
Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
Interventions
Gemcitabine Hydrochloride, Cisplatin, Pegfilgrastim, Conventional Surgery, Radical Cystectomy, Chemoradiotherapy
Drug · Biological · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
424
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 293 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 26, 2026, 5:03 AM EDT
Completed Phase 2Phase 3 Interventional

Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

NCT00406068
View directory record Official record
Conditions
Bladder Neoplasms
Interventions
Mycobacterial cell wall-DNA complex
Drug
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Phoenix, Arizona • San Diego, California • New Britain, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Jun 26, 2026, 5:03 AM EDT